Clinical trial
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance…
NCT00396240 · AstraZeneca, Industry · Withdrawn
Key facts
| NCT number | NCT00396240 |
|---|---|
| Title | ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals |
| Official title | ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals |
| Lead sponsor | AstraZeneca, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Primary Hypercholesterolaemia |
| Intervention type | Drug, Procedure |
| Interventions | Rosuvastatin, Initiatives to improve compliance |
| Enrollment | 1,294 |
| Start date | Feb 1, 2002 |
| First posted | Nov 6, 2006 |
| Last update posted | Mar 26, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: